

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 October 2002 (03.10.2002)

PCT

(10) International Publication Number
WO 02/077152 A1

(51) International Patent Classification⁷: **C12M 1/20**,
G01N 33/50, 33/53, C12Q 1/70, 1/68

(21) International Application Number: PCT/CN02/00209

(22) International Filing Date: 28 March 2002 (28.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
01105795.5 28 March 2001 (28.03.2001) CN
01112783.X 27 April 2001 (27.04.2001) CN
01113323.6 11 July 2001 (11.07.2001) CN
01126115.3 12 July 2001 (12.07.2001) CN
01126480.2 14 August 2001 (14.08.2001) CN
01126929.4 29 September 2001 (29.09.2001) CN
01126932.4 29 September 2001 (29.09.2001) CN
01132292.6 23 November 2001 (23.11.2001) CN

(71) Applicant (for all designated States except US):
**GENETECH BIOTECHNOLOGY (SHANGHAI)
COMPANY LIMITED** [CN/CN]; 6/F, Building 25,
No.69, Guiqing Road, Shanghai 200233 (CN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHEUNG, To**
[CN/CN]; Flat D, 30/F., Tower 6, Island Resort, 28 Siu
Sai Wan Road, Hong Kong (CN). **LI, Bin** [CN/CN]; 6/F,
Building 25, No.69, Guiqing Road, Shanghai 200233
(CN). **PENG, Yongji** [CN/CN]; 6/F, Building 25, No.69,
Guiqing Road, Shanghai 200233 (CN). **REN, Yiping**
[CN/CN]; 6/F, Building 25, No.69, Guiqing Road, Shang-
hai 200233 (CN). **GE, Haipeng** [CN/CN]; 6/F, Building
25, No.69, Guiqing Road, Shanghai 200233 (CN). **DENG,
Fuqiao** [CN/CN]; 6/F, Building 25, No.69, Guiqing Road,

Shanghai 200233 (CN). **DING, Li** [CN/CN]; 6/F, Building
25, No.69, Guiqing Road, Shanghai 200233 (CN). **LI,
Hongmei** [CN/CN]; 6/F, Building 25, No.69, Guiqing
Road, Shanghai 200233 (CN). **CAI, Qifeng** [CN/CN];
6/F, Building 25, No.69, Guiqing Road, Shanghai 200233
(CN). **CHEN, Ying** [CN/CN]; 6/F, Building 25, No.69,
Guiqing Road, Shanghai 200233 (CN).

(74) Agent: **BEIJING SANYOU INTELLECTUAL PROP-
ERTY AGENT LTD.**; No.40 North Sanhuanzhonglu
Road, Beijing 100088 (CN).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: DEVICE AND METHOD FOR DETECTION OF MULTIPLE ANALYTES

(57) Abstract: A device is provided for the detection of multiple analytes in at least one sample. The device contains a solid substrate with a test surface. On the test surface is defined at least one reaction area containing at least one array of discrete test sites. Each of these test sites have a test molecule immobilized on to it, and different test sites may have different test molecules immobilized thereon. A divider is provided for attachment onto the solid substrate. The divider contains a plurality of holes provided on an attachment surface. The attachment surface is complementary to the test surface of the solid device and is adapted for reversible attachment thereto such that when the two parts are attached, each of the holes is adjoined with a portion of the test surface to create a plurality of leak-proof chambers. The test surface within the chamber contains a plurality of test sites exposed within the chambers. Each of the chamber is preferably provided with an opening that is accessible from the exterior such that fluid introduced into the chambers may be contacted with the exposed test sites for testing. In another aspect of the present invention, a method is provided for analysing multiple analytes in the same samples.



WO 02/077152 A1

DEVICE AND METHOD FOR DETECTION OF MULTIPLE ANALYTES

FIELD OF INVENTION

5 The present invention relates to a device and method for detecting and/or quantifying more than one analyte in a sample.

BACKGROUND OF INVENTION

10 Diagnostic testing device and method for detecting various diseases and human conditions have been described in many literature and patent documents. With the advances of medical treatment and diagnostics, it has become increasingly important to monitor the state of health of a person for early diagnosis of disease conditions. The ability to test for different analytes in the same sample is a goal that many have been pursuing. Ideally, a method for analysing a single sample using a single test device should provide diagnostic
15 information for multiple analytes in order to conserve reagents and human resources required.

 US Patent No. 6126899 to Woudenberg et al. is directed to a method and device for simultaneously testing a sample for the presence or absence of one or more sample analytes. The device is described as having a substrate that defines a sample – distribution network
20 having a series of chambers with each chamber having a specific reagent effective to react with an analyte. Although, multiple analytes may be analysed using the aforementioned system, the device contains numerous chambers and grooves that would require a solid substrate to be manufactured specifically for this purpose.

 European Patent Application No. EP0874242 to Fitzgerald et. al. describes a solid
25 state device for performing multi-analyte assays in which a substrate and a multiplicity of discrete reaction sites are covalently bonded with a ligand. This application discloses a device with various channels and chambers for accommodating samples to be analysed. The invention further provides an integrated analytical system for the simultaneous detection of different analytes in a multi-analyte format.

30 Although, the above-described systems are capable of analysing multiple analytes from a sample, there is a continual need to provide improved systems that have reduce costs

for manufacturing the device and for testing the samples. There is also a need to reduce sample and reagent volume. It is therefore an object of the present invention to provide improved diagnostic systems for multiple analytes.

5 SUMMARY OF INVENTION

According to one aspect of the present invention, a device is provide for the detection of multiple analytes in at least one sample. The device contains a solid substrate with a test surface. On the test surface is defined at least one reaction area containing at least one array of discrete test sites. Each of these test sites have a test molecule
10 immobilized on to it, and different test sites may have different test molecules immobilized thereon. A divider is provided for attachment onto the solid substrate. The divider contains a plurality of holes provided on an attachment surface. The attachment surface is complementary to the test surface of the solid device and is adapted for reversible attachment thereto such that when the two parts are assembled, each of the holes is adjoined
15 with a portion of the test surface to create a plurality of leak-proof chambers. The test surface within the chamber contains a plurality of test sites exposed within the chambers. Each of the chamber is preferably provided with an opening that is accessible from the exterior such that fluid introduced into the chambers may be contacted with the exposed test sites for testing.

20 In the preferred embodiment, the chamber is a well that is created with the test surface of the solid substrate acting as a base and part of the divider acting as the retaining wall such that a plurality of test sites are expose on bottom of the well within the chamber.

In another aspect of the present invention, the test molecules consist of at least one ligand and at least one antibody. The ligand is immobilized onto one test site and the
25 antibody immobilized onto a different test site within the same chamber, such that the binding reaction of the corresponding cross-reactive analytes in the same sample is achieved simultaneously within the same reaction area.

In the preferred embodiment of the present detection device, the solid substrate is a chip with a flat top surface having a plurality of reaction areas defined thereon. Each test
30 area contains at least one array of discrete test sites having a test molecule immobilized thereon. The divider is a sheet having holes defined by a frame with each hole corresponding to a reaction area. The frame of the sheet is adapted for reversible coupling onto the flat surface of the chip such that a leak-proof well is created therebetween. The

coupling may be done by any conventional means, including mechanical means such as, but not limited to, clips and screws, and chemical means such as glue and adhesives. Within each well, one reaction area of the top surface of the chip forms the base of the well and the corresponding parts of the frame of the sheet forms the dividing walls between the wells.

5 The sheet is detachable such that after sample reaction, the sheet may be removed and the chip may be inserted into a standard chip reader for result reading and analysis. One advantage of this prefer embodiment is that many standard chip readers may be used to analyse test results. The removable divider sheet, when attached to the chip, creates an assembled device containing a system of wells where reactions of different samples may
10 occur. The number of wells can be determined according to the user's requirements and the divider sheet with the required holes produced accordingly. The present invention has provided a truly versatile biochip and method for detecting multiple analytes and samples in a standard chip format.

In another aspect of the present invention, a method is provided for analysing
15 multiple analytes in the same samples. The method comprises the steps of defining a plurality of discrete and spatially separate test site on a test surface, and immobilizing one test molecule onto each test site such that a plurality of test molecule are immobilized thereon. A fluid proof barrier around each test area is then created and a sample for analysis is added to each test area with the appropriate test reagents.

20

BRIEF DESCRIPTION OF DRAWINGS

Figure 1A is a diagram to show a top view of a solid substrate according to one embodiment of the present invention.

Figure 1B is a diagram to show a top view of a divider sheet complementary to the
25 substrate shown in Figure 1A according to the same embodiment.

Figure 1C is a diagram to illustrate the top plan view of a device according to the present invention with the top divider sheet showing Figure 1B attached to the substrate shown in Figure 1A.

Figure 1D is a diagram to show a cross sectional side view across line A-A of Figure
30 1C.

Figure 1E is a diagram to show a cover sheet according to the same embodiment for covering the device shown in Figure 1C.

Figure 2A is a diagram to illustrate the top view of a substrate according to a second embodiment of the present invention. The positions of the test sites are shown by dotted circles.

Figure 2B is a diagram to illustrate the top view of a divider sheet complementary to the substrate shown in Figure 2A according to the same embodiment thereof.

Figure 2C is a diagram to illustrate the top view of the assembled device according to the second embodiment of the present invention with the divider sheet attached to the top surface of the solid substrate. The positions of the test sites are again shown by dotted circles.

Figure 2D is a diagram to illustrate the cross sectional side view along line B-B of the device in Figure 2C.

Figure 3A shows a test area according to a third embodiment of the present invention.

Figure 3B shows a test area according to the fourth embodiment of the present invention.

Figure 4A is a diagram to illustrate the top view of a hepatitis biochip according to one preferred embodiment.

Figure 4B illustrates a test area in a hepatitis protein chip for detecting various hepatitis antibodies of the same preferred embodiment. 60: human IgG Positive control; 62: human serum albumin (HSA) Negative control; 64: HAV Ag; 66: HCV Ag; 68: HDV Ag; 70: HBs Ag; 72: HBe Ag; 74: HBc Ag; 76: HEV Ag.

Figure 4C illustrates a test area in hepatitis protein chip for detect various hepatitis antigens of the same preferred embodiment. 60a: HBsAg Positive control; 60b: HBeAg Positive control; 60c: AFP Positive control; 60d: HDVAg Positive control; 62: Negative control; 78: HBs Ab; 80: HBe Ab; 82: AFP Ab; 84: HDV Ab.

Figure 4D is an example of the expected result of the diagnosis of a HAV infected patient with Anti-HAV-IgG present in the serum using the chip shown in Figure 4A – Figure 4C. The two test areas of the chip are shown.

Figure 4E is an example of the expected result of the diagnosis of a HBV infected patient with serum containing HBsAg, HBeAg and HBcAb using the chip shown in Figure 4A – Figure 4C. The two test areas of the chip are shown.

Figure 5A illustrates a test area of a ToRCH protein Chip according to a further preferred embodiment of the present invention. 86: Toxoplasma gondii; 88: Rubella virus; 90: CMV; 92: HSV 1; 94: HSV 2; 96: Positive control; 98: Negative control.

5 Figure 5B is an example of the expected result of Figure 5A in the diagnosis of a rubella virus infected patient using a ToRCH protein Chip. (For ease of illustration, only one test area or well is shown; test performed using a patients serum containing RV IgG)

Figure 5C is an example of the result of Figure 5B in the diagnosis of a CMV infected patient. (For ease of illustration, only one test area or well is shown; test performed using a patient serum containing CMV IgM)

10 Figure 6A illustrates a test area of a cancer protein chip according to yet another embodiment of the present invention.

Figure 6B is an example of the expected result of Figure 6A in the diagnosis of a liver cancer patient using serum of the patient.

Figure 7A illustrates a test area of autoimmune disorder protein chip.

15 Figure 7B is an example of the expected result of Figure 7A in the diagnosis of a systemic lupus erythematosus patient using the autoimmune disorder protein chip. (For ease of illustration, only one test area is shown)

Figure 7C is an example of the result of Figure 7A in the diagnosis of a rheumatoid arthritis patient using the autoimmune disorder protein chip. (For ease of illustration, only one
20 test area is shown).

DETAILED DESCRIPTION

As defined herein, sample includes, but is not limited to, any solution, mixture or biological fluid that contains any analytes to be tested. Sample includes positive control and
25 negative control serum and biological fluid. A leak-proof chamber means that the chamber is capable of holding fluid in at least one direction without leakage or spillage provided that the volume of fluid is adapted to be contained within the size of the chamber. A leak-proof chamber includes enclosed structures or structures with openings. Ligand refers to any antigen or molecule that is capable of reacting with an antibody in an antibody-antigen
30 binding reaction, a substrate in an enzyme-substrate binding reaction, or a molecule that can be recognised and bound by a receptor including but not limited to nucleic acids,

chromosomal fragments, proteins, peptides, glycoprotein, lipid, polypeptides, antibiotics, steroids and other organic molecules.

In the preferred embodiment of the present invention, and referring to Figures 1A to 1D, a biochip consisting of a glass slide **20** is provided with a separate top divider sheet **22**.

5 The divider sheet **22** as shown in Figure 1B, may be made of any inert material and preferably of a flexible material such as plastic, membrane, latex, ceramic, rubber, resin, PVC or silicon. Holes **22a** are punched into the divider sheet such that a frame **22b** is formed around each hole. Frame **22b** then acts as side walls and the top surface of the slide acts as the base to create a well or chamber **24** therebetween as shown in Fig. 1D. The size
10 of the top divider sheet is preferably of the same dimension as or slightly shorter than the slide and contains glue on the bottom side such that it may be glued directly on the glass slide **20**. In the preferred embodiment, the glue is strong enough to allow the top divider sheet to be attached to the glass slide such that wells **24** are created therebetween. The wells should be leak-proof such that when the appropriate amount of fluid is applied into each
15 well the fluid would not flow into an adjacent well through the adjoining area. The glue should also be inert and of a material that allows the divider sheet to be detached from the slide at the convenient of the user. The number of rows or columns in each array of test sites may vary according to the user's need. The thickness of the divider sheet is dependant on the volume of reaction that is required in each well and may be determined by one skill in
20 the art without undue experimentation. For example the sheet may be 1 to 3 mm thick. The holes and frame can be any size or shape according to the user's need. As an illustration, holes with inner dimensions from 0.3cm x 0.3cm to 0.4cm x 0.6cm to 1.2cmx1.2cm may be used. The width of the dividing wall such 22b or 34a can range from 0.15cm to 0.6 cm. The number of holes can also be varied accordingly, such as in a 1x2, 2x3, 3x10, 3x5, 2x5, 3x8
25 and 4x8 array format.

In the simplest embodiment, a single test molecule may be immobilized into one test area **20a** of the glass slide that correspondence to a specific well. For example, in Figure 1B, the position of hole **H1** would correspond to the position of test area **TA1** as shown in Figure 1A. One test molecule is immobilized onto test surface **TA1** such that when the top
30 divider sheet is attached and glued onto slide **20**, a well **W1** is created with the bottom of the well corresponding to test area **TA1** as shown in Figure 1C. In this particular example, there is only one test molecule and therefore only one test site that is found within each test area. An optional cover sheet **21** as shown in Figure 1E is also provided as a lid that can be placed onto to the outer surface of the divider to cover the solutions during incubation of the

binding reaction to prevent evaporation, spillage or contamination. The cover sheet can then be removed according to the user's needs. The cover sheet may be made from any inert material such as the material used for the divider. An example is polyester film.

In another embodiment, a plurality of test sites are defined in each test area such that a plurality of test molecule may be found within each chamber or well. Referring first to Figure 2A, another glass slide **29** according to the present invention is shown with two test areas **30** defined thereon. Each test area is shown as a square with dotted lines. Within each test area are test sites **32** defined in a 3x3 array and shown as circles. Figure 2B shows a complementary divider sheet **34** with two larger holes **36** punched therein. The remainder of the sheet forms a frame **34a**. Figures 2C & 2D show the assembled device according to this embodiment of the present invention in which two large wells **40** are formed between the divider **34** and the glass slide **29**. From the illustration shown, it is clear that in this particular example, a maximum of nine different test molecules may be immobilized into the same test area and that multiple analytes may be detected using this format.

Figure 3A shows another embodiment of the present invention in which one test area **41** (corresponding to the base of one chamber) contains nine arrays of 4x4 test sites. The other test area and the solid device are not shown for ease of illustration. It is clear that different chambers or test areas of a similar kind may be defined according to the user's requirement. Furthermore, different test areas on the same test surface may have different test site arrangements. In this example, the open circles **42** define test sites with an assay molecule immobilized thereon whilst the solid circles **44** are positive control sites with a positive control molecule immobilized thereon. The dotted circles **46** define test sites in which the negative control is immobilized thereon. The positive control molecule is expected to react with an analyte known to be present in the sample while the negative contain a test molecule that is not expected to react with any analyte in the sample. The assay molecule is one that cross reacts with an analyte (referred to as the assay analyte for ease of explanation) with unknown levels in the sample. The assay analyte is the subject of the diagnostic test. This single test area (i.e. a single well) in this example contains three rows of the 4x4 array of test sites (rows A to C) and three columns of the 4x4 arrays of test sites (columns 1 to 3). Arrays **A1**, **A2**, **A3**, **B1**, **B2**, **B3** and **C1** are identical. The positive control and assay molecule are arranged in interpolating positions. The negative control is immobilized onto test sites in Arrays **C2** and **C3**. The entire well **41** is adapted to receive one sample such that the reaction for all the test sites can occur simultaneously and within the same reaction area. Thus in this example, three different test molecules are immobilized

in the same test area for analysis. Furthermore, the multiple repetition of test sites for each test molecule allows for extremely accurate detection to occur.

Although, the examples described above show Arrays **A1**, **A2**, **A3**, **B1**, **B2**, **B3** and **C3** as having the same three assay molecules arranged in an identical format, it is clear that a different assay molecule may be immobilized onto each of these arrays in the same reaction area. For example, one assay molecule (e.g. the positive control molecule) may be immobilized into the 8 reaction sites in Array **A1** while a second and different assay molecule (e.g. the negative assay molecule) is immobilized onto the 8 reaction sites in Array **B3**. Furthermore, it is clear that numerous different assay molecules may also be immobilized into these seven arrays depending on the number of duplicates that are required to produce the accuracy of the desired level.

Figure 3B shows another embodiment of the present invention in which the test area corresponding to one well or chamber contains a 9x9 array having a center row and a center column surrounded by four quarters. The negative control **54** is immobilized into a "cross" or cruciform configuration along the center column and center row while the positive control **50** and assay molecule **52** are arranged in interpolating positions within the four quarters. Using this format, it is clear that upon a successful experimental run in which the negative control produces no or low signal according to expectations, the four quarters would be elucidated distinctly. There is thus an advantage of this format in providing clear and unambiguous results even on simple visual inspection.

The following examples illustrate various specific embodiments of the present invention and is meant to teach one of ordinary skill in the art to make and use the present invention. These examples are meant to be illustrations only and are not intended to the limit scope of the claims as appended herewith. In the following examples, test molecules are also referred to as probes or markers. Test areas are sometimes referred to as grids and test sites as subgrids.

EXAMPLE 1

METHOD OF IMMOBILIZING A LIGAND ONTO A TEST SITE

Protein chip is prepared by printing and immobilized probes in a predefined grid and sub-grid pattern on microscopic solid substrate by microarrayer. The probes can be either antigens or antibodies, in the form of proteins, polypeptides or peptide, and are capable of

binding to target proteins in test samples. The micro solid substrate can be derivatized glass microscopic slide, nitrocellulose membrane or silica. As much as 2390 protein spots can be printed one every 1cmx1cm area on glass substrate. Samples used in the reaction can be in the forms of plasma, serum, blood or other body fluid. The entire reaction procedure will be carried out in situ on the solid substrate.

Fabrication of biochip:

1. Probes in appropriate dilution are added in individual well in microtitre plate, also known as source plate.
2. The source plate is placed in the appropriate slot in a robotic microarrayer (Prosys4510, from Cartesian Technology, CA, USA)
3. Software controls microarray pin to draw sample from the source plate.
4. Samples are printed on derivatized microscopic slide by dwelling the sample-filled pin on the surface of the slides.
5. The printed biochip is incubated at 37°C for 1 hour to immobilize protein probes on the surface of substrate.
6. The remaining surface of substrate is blocked by Bovine Serum Albumin (BSA) and Tween 20 in TBS buffer [0.02M Tris-HCl, 0.137M NaCl, pH 7.6] for 1h at 37°C.
7. Wash in double distilled water and dry at room temperature
8. Incubate the biochip in 0.3% sodium borohydride (NaBH_4) at 37°C for 5 to 10 min. to reduce free aldehyde groups on glass surface.
9. Wash with double distilled water and dry at room temperature.
10. The fabricated biochip is sealed under darkness at 4°C.

Methods of assembling the device:

1. The outer dimension of plastic material for making multi-chamber plastic device (the divider sheet) should match that of the solid substrate.
2. Number of chambers per device can be ranging from 1x2 to 4x10.
3. The distance between the centers of each two adjoining chambers is the multiple of 4.5mm which matches the geometry of 384 and 96 microtitre plates, pin distance of pin head of microarray and multichannel pipettmen.
4. The thickness of the plastic, determining the depth of each chamber, should be at least 1mm and can be ranging from 1 to 3mm.
5. One side of the multi-chamber plastic device should be sticky and can tightly adherent to the solid substrate to form leak-proof wells for the reaction. Such a

device should be water-resistance, leak-proof, rigid and inert when soak in aqueous solution and used under hydraulic pressure.

6. Protein probes are microarrayed onto each chamber for biochip fabrication for multi-marker, multi-specimen usage.

5 7. A polyester film, which size matches the outer dimension of the multi-chamber plastic device, with single-sided adhesive is optionally used to cover on the multi-chamber biochips, forming well-isolated and enclosed chambers for the reaction.

8. The whole set up in the multi-chamber biochip can tolerate reaction temperature between -40°C and 95°C , UV treatment and is water-resistance.

10 9. The bonding between the polyester film to the plastic of the multi-chamber device should be weaker than that of the device to the solid substrate. The removal of the film at each reaction step should not alter the structure of multi-chamber biochips.

10. Upon reaction completion, the plastic device can be disassembled from the solid substrates for analysis in a conventional microarray scanner (Scanarray4000, Packard Bioscience (now known as PerkinElmer Life Sciences, CT, USA))

15 Immobilization of protein to solid substrate can also be achieved through physical interaction e.g. by charge (e.g. negative charged protein bonds with positively charged membrane or positively charged metal surface) by hydrophobic interaction (hydrophobic protein bonds to hydrophobic membrane), by detention (protein of a certain size being
20 impeded in porous substrates such as membranous or gel type of substrates) and through chemical interaction (e.g. bonding with epoxy slide, silanized slide, silyated slide.)

EXAMPLE 2

METHOD OF DETECTING AN ANTIBODY IN HUMAN SERUM USING A 25 CROSS-REACTIVE ANTIGEN IMMOBILIZED ONTO A BIOCHIP

Reaction and detection:

1. Remove the biochip from its package.
2. Test samples (patient sample, positive and negative sera controls) are added separately to individual chambers in a biochip and allowed to react at 37°C for 1 h.
- 30 3. Unbound reactants are washed with washing buffer with sodium salt like PBS or TBS. [PBS: 0.137M NaCl, 0.027M KCl, 0.0043M $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 0.0014M KH_2PO_4 , pH7.3] [TBS: 0.02M Tris-Cl, 0.137M NaCl, pH7.6]
4. Remove excess buffer and allowed to dry at room temperature for 5 min.

5. Blocking solution [1% bovine serum albumin in TBS or PBS] is added to the biochip
6. Wash and dry the biochip
7. Fluorescence labeled compound (secondary antibodies or antigens) is diluted in blocking solution is added to the biochip and incubated at 37°C for 0.5h.
8. Wash, remove the divider sheet from the biochip and spin-dry.
9. The image is scanned by microarray scanner. Fluorescence intensity of each spot is recorded and used in data analysis and for diagnosis.

In another embodiment, steps 7 to 9 above are replaced by step 7a to 13a as described below :

- 7a. Biotin conjugated secondary antibody is diluted in blocking solution is added to the biochip and incubated at 37°C for 0.5h.
- 8a. Wash and dry the biochip.
- 9a. Streptavidin molecule in blocking solution is added and incubated at 37°C for 0.5h.
- 10a. Wash and dry.
- 11a. Fluorescence compounds (biotin or anti-streptavidin antibody) is diluted in blocking solution and incubated at 37°C for 0.5h.
- 12a. Wash, remove the divider sheet from the biochip and spin-dry.
- 13a. The image is scanned by microarray scanner. Fluorescence intensity of each spot is recorded and used in data analysis and for diagnosis.

EXAMPLE 3

METHOD OF DETECTING AN ANTIGEN USING A CHIP WITH A CROSS-REACTIVE ANTIBODY IMMOBILIZED THEREON

Reaction and detection:

1. Remove the biochip from its package.
2. Test samples (patient sera, positive and negative sera controls) are added onto the biochip and allowed to react at 37°C for 1 h.
3. Unbound reactants are washed with washing buffer with sodium salt like PBS, TBS. [PBS: 0.137M NaCl, 0.027M KCl, 0.0043M Na₂HPO₄•7H₂O, 0.0014M KH₂PO₄, pH7.3] [TBS: 0.02M Tris-Cl, 0.137M NaCl, pH7.6]
4. Remove excess buffer and is allowed to dry briefly at room temperature for 5min.

5. Blocking solution [1% bovine serum albumin in TBS or PBS] is added to the biochip
6. Wash and dry the biochip
7. A second primary antibody diluted in blocking solution is added to the biochip and incubated at 37°C for 0.5h.
8. Wash, spin-dry and block again.
9. Alkaline phosphatase (AP) or horse radish peroxidase conjugated anti-human IgG antibody (secondary antibody) diluted in blocking buffer is added and incubated at 37°C for 0.5h.
10. Appropriate chemiluminescent substrates (Luminol for HRP from ICN Biomedicals Inc (CA, USA) or 1,2-dioxetane-based substrate for AP from Pierce Chemical Company (IL, USA)) are added and incubated at room temperature for 1 min. (according to the manufacturer's manual)
11. The image is scanned by microarray scanner. Chemiluminescence intensity of each spot is recorded and used in data analysis and for diagnosis.

EXAMPLE 4A

DIAGNOSIS OF HEPATITIS IN HUMAN SERUM

This embodiment includes the fabrication of a protein chip and its application in diagnosis for acute hepatitis, chronic hepatitis, liver cirrhosis and liver cancer that is caused by hepatitis virus infection.

Markers for hepatitis A infection diagnosis are hepatitis A antibodies (anti-HAV IgG or IgMAb); for hepatitis B are hepatitis B surface antigen (HBsAg), hepatitis B 'e' antigen (HBeAg), hepatitis B surface antibody (HBsAb), hepatitis B 'e' antibody (HBeAb) and hepatitis core antibody (HBcAb); for hepatitis C are hepatitis C antibodies (anti-HCV IgG or IgM); for hepatitis D are hepatitis D antibodies (anti-HDV IgG or IgM); and for hepatitis E are hepatitis E antibodies (anti-HEV IgG or IgM). Alpha-fetoprotein (AFP) is the marker to include in the biochip for liver cancer diagnosis. Probes or test molecules that can specifically react to these markers are printed on solid substrate during biochip fabrication.

An example of a test area is shown in Fig. 4A, 4B, 4C, 4D and 4E. This example illustrates the use of multiple repetitions provided in two test areas 56 and 58 on the same chip (Figure 4A) for data analysis. These two test areas would serve as the bottom of two wells when an appropriate divider with two corresponding holes is placed onto this biochip for sample introduction. The advantages of this arrangement will be apparent upon

explanation of the figures below. The high number of repetitions of each test molecule increases the confidence in data analysis and minimizes the geographic and machine variation during data collection, hence improving the accuracy in each biochip experiment. Moreover, the distinct pattern as illustrated below facilitates the identification of spots in a high density array.

In this example, there are two test areas or grids **56** and **58** defined on this Biochip. Grid or test area **56** contains seven subgrids or arrays **56a** of test sites. Within each sub-grid **56a**, a positive control and a assay molecule are immobilized with multiple repetitions in an array configuration. Dotted line **56b** represents the positions on which multiple test sites of the negative control are defined.

Referring to Figure 4B the test area or grid **56** is shown in greater detailed. The dotted circle **62** represent the negative controls that are found spotted in multiple repetitions across rows and columns that delineate the boundaries of each sub-grid. In each sub-grid, a positive control **60** and a test molecule (one of the hepatitis antigens) are immobilized. The test molecule immobilized into each subgrid is a different hepatitis viral antigen.

For example, in array A1, there are 16 test sites arranged in a 4 x 4 arrangement with the Human IgG as the positive control **60**; and the test molecule hepatitis A antigen (HAV Ag) **64** immobilized in an interpolating arrangement. Six other arrays (A2 – A7) are illustrated with the only difference being the test molecule immobilized thereon (HAV antigen **64**, HCV antigen **66**, HDV antigen **68**, HBs antigen **70**, HBeAg **72**, HBc antigen **74** and HEV antigen **76** immobilized onto subgrids A1 to A7 respectively).

Referring now to test area **58** as shown in Figure 4C, the test site arrangement in this area is different from that of test area **56**. In test area **58**, the negative control is immobilized onto multiple test sites that are arrange in a cruciform configuration across the center of the test area along line **58a** of Figure 4A. The cruciform arrangement of the negative control test sites divide the test area into four quarters. Four other arrays or subgrids (B1 to B4) are provided therearound. In array B1 as shown in Figure 4C, the positive control hepatitis B surface antigen **60a** and the test molecule anti-hepatitis B surface antigen antibody (HBs Ab) **78** are immobilized onto 16 separate and discreet test sites in an interpolating relationship. The other three quarters (B2 to B4) contain the positive control hepatitis BeAg **60b** in combination with the anti-hepatitis B “e” antibody **80**, positive control AFP **60c**, the anti-AFP antibody **82** and the positive control hepatitis D virus antigen **60d**, the anti-hepatitis D virus antibody **84** respectively.

Method for binding reaction:

Table 1 shows the spotting conditions for each of the test molecule on the biochip. Column 2 shows the concentration of the protein solution used for spotting while column 3 indicates the estimated size of each spot. The amount of protein that is actually immobilized onto each test site may be estimated based on the assumption that a semi-spherical spot is provided on each reaction site. The entire spot is allow to dry and most of the protein is considered immobilized onto the surface of the test site.

Table 1

spots	spot concentration	spot size	Time for binding reaction
HBsAG	0.4mg/ml	160um	60 – 90 min
HBsAb	2mg/ml	160um	60 – 90 min
HBeAg	0.8mg/ml	160um	60 – 90 min
HBeAb	2mg/ml	160um	60 – 90 min
HBcAb	0.15mg/ml	160um	60 – 90 min
HAV IgG	0.8mg/ml	160um	60 – 90 min
HCV IgG	0.1mg/ml	180um	60 – 90 min
HDV IgG	0.125mg/ml	160um	60 – 90 min
HEV IgG	0.8mg/ml	150um	60 – 90 min

During a binding reaction patient serum is added into chambers 56 and 58 using a method similar to the one described for Example 2 and Example 3 respectively. In this example there are only two test areas shown in the biochip, one testing for hepatitis antibodies and the other for the presence of hepatitis antigen in the serum and therefore only one test serum can be tested thereon. The other test sera such as the positive and negative control sera can be applied to two separate and identical biochips in order to obtain the negative and positive results. After reaction completion, the chip is scanned and a fluorescence signal intensity from each spot is recorded.

EXAMPLE 4B**DIAGNOSIS OF HEPATITIS IN HUMAN SERUM USING MULTIPLE WELLS**

This example shows how the system described in Example 4A may be adapted for use in a biochip that contains multiple wells to increase the number of samples that may be

tested in the same biochip. In this example, an array of three rows and eight columns such as the one shown in Figure 1A is used for diagnosis of hepatitis in patients. For the ease of explanation, the rows of test areas are denoted as rows A, B and C from top to bottom and the columns of test areas are denoted as columns 1 to 8 respectively. In this example, the 12 test areas within columns 1 to 4 of the biochip contains test sites that are identical to the one shown in test area 56 of Figure 4B. The 12 test areas in columns 5 to 8 each contains an array of test sites that are identical to that found in test area 58 of Figure 4C. Using this arrangement, it can be clearly seen that for diagnosis of hepatitis antigens in the serum, there are a total of 12 test areas (i.e. wells) available. In this example, a positive control serum obtained from a patient with known hepatitis infection is added to test area A1. A negative control serum obtained from a healthy individual with no hepatitis infection is used for diagnostic reaction in well B1. The remaining 10 wells (wells A2 to A4, B2 to B4 and C1 to C4) may be used to test unknown patient sera for the presence of hepatitis antigens. In the same manner, a positive control sera is used in well A5 to provide a positive control for hepatitis antibodies while a negative control sera may be added to well B5. Their remaining wells (A6 to A8, B6 to B8, C5 to C8) may be used for testing unknown sera. The binding reaction and detection system used is the same as the one described in example 4A.

Method for result analysis:

R value = mean value of signal intensity of test probes falling within the 95% Gaussian distribution divided by that of positive control probe within the same subgrid.

R values from test samples in test chambers are Rs.

R value from positive control sample in positive reference chamber is Rp.

R value from negative control sample in negative reference chamber is Rn.

$R_{co} = \text{as } \frac{1}{2}(R_n + R_p)$.

There are three approaches to interpret the data

- a. Method I: Individual sample with its Rs greater than 0.05 is defined as positive to the test probe; Rs between 0.02 and 0.05 is border-line and test should be repeated; and less than 0.02 is negative.
- b. Method II: Individual test sample with its Rs/Rn greater than 2.1 is defined as positive, Rs/Rn between 1.5 and 2.1 is borderline; and Rs/Rn less than 1.5 is negative.
- c. Method III: Individual test sample with its Rs greater than Rco is positive; and less than Rco is negative.

This invention facilitates data comparison within chamber and between chambers across the same chip. The geographic variation that may affect the signal intensity is minimized using this design in microarraying and data manipulation method.

Employing the method described above, hepatitis serum standards were obtained from the State Drug Administration of China (SDA) and used as test sera to check the accuracy and sensitivity of the method and device according to the present issues.

To ensure accuracy and precision of diagnostic kits in China, SDA sets the standard of sensitivity and specificity. The sensitivity test sets the weakest reactive range of diagnostic kits. The method invention according to the present passed the sensitivity test with 100% accuracy. Column 2 of Table 2 represents samples that were provided by the States Drug Administration of China as reference samples that have to be used to check the sensitivity of all diagnostic kits that are registered in China for clinical use. For HbsAg and HbsAb, a reference standard of 1 ng/ml and 10 mIU/ml are used respectively.

Table 2 : Sensitivity test using SDA sensitivity standards

Hepatitis Markers	SDA sensitivity reference ¹	Results of biochip diagnosis (fluorescence intensity) [Inventor: please verify]		
		Method I	Method II	Method III
HbsAg ²	≤1ng/ml	0.09	2.2	+
HbsAb ³	≤10mIU/ml	0.12	2.4	+
HbeAg ⁴	1# ≥ 1:64	0.10	2.4	+
	2# ≥ 1:128	0.07	2.2	+
	3# ≥ 1:32	0.10	2.3	+
HbeAb ⁵	55# ≥ 1:32	0.08	2.2	+
	57# ≥ 1:32	0.07	2.1	+
	61# ≥ 1:32	0.07	2.2	+
HbcAb ⁶	2# ≥ 1:32	0.08	2.2	+
	3# ≥ 1:8	0.11	2.4	+
	4# ≥ 1:16	0.09	2.2	+

['+' is test positive, '-' is test negative

1. SDA standard panel kit lot number. 9909

2. HBsAg (hepatitis B surface antigen); 3.HBsAb (antibody against hepatitis B surface antigen); 4. HBeAg (hepatitis B 'e' antigen); 5. HBeAb (antibody against hepatitis B 'e' antigen); 6. HbcAb (antibody against hepatitis B core antigen)

5

Table 3 : Specificity test using SDA standards

Markers	SDA specificity reference (no. of negative determined by the current method verse total negative standard analysed) ¹	Results of biochip diagnosis		
		Method I	Method II	Method III
HbsAg ²	20/20	0-0.018	0-1.38	-
HbsAb ³	20/20	0-0.019	0-1.49	-
HbeAg ⁴	15/15	0-0.016	0-1.46	-
HbeAb ⁵	15/15	0-0.016	0-1.46	-
HbcAb ⁶	15/15	0-0.016	0-1.48	-

Footnotes: ['+' is test positive, '-' is test negative

1. SDA standard panel kit lot number. 9909

2. HbsAg (hepatitis B surface antigen); 3.HbsAb (antibody against hepatitis B surface antigen); 4. HBeAg (hepatitis B 'e' antigen); 5. HBeAb (antibody against hepatitis B 'e' antigen); 6. HbcAb (antibody against hepatitis B core antigen).

Using these three methods described above, the result are shown in the next three columns. For HbeAg, HbeAb and HbcAb, three separate unknown samples were provided by SDA and various dilutions were used to dilute the serum as indicated under column 2 (sample Nos. 1, 2 and 3 for HbeAg; Nos. 55, 57 and 61 for HbeAb; Nos. 2, 3 and 4 for HbcAb). The results of fluorescence intensity detection after the binding reaction are shown in the next corresponding column.

Table 3 shows the results of specificity test that are required by the SDA. In these test, negative sera were provided by the SDA for testing of the respective antigens or antibodies as indicated in the first column. The results are shown in the next few columns. In column 2, the denominator of the fraction indicate the number of samples that were provided by the SDA while the numerator of the ratio represents the number of sample that were tested negative. According to SDA requirements, no false positives are tolerated.

Thus, using the method according to the present invention, specificity is very high and there is little cross reactivity among patient's sera with various non-specific antigen or antibody.

Figure 4D is an example of the expected result of a HAV infected patient. Positive signals are recorded only in test sites 64 in test area 56 and all positive controls in both test areas 56 and 58. Such a result would show that the test sera antibody is directed against HAV Ag and not other test molecules and specificity of the test is good.

Figure 4E is an example of the expected result of a HBV infected patient. Positive signals are expected in test sites 74 in test area 56, and test sites 78 and 80 in test area 58; and also all the positive controls in test areas 56 and 58.

EXAMPLE 5

ANTENATAL TESTING IN PREGNANT PATIENTS

This embodiment describes a biochip to be used to test the serum of pregnant women for antenatal testing purposes. Toxoplasma gondii, Rubella virus, Cytomegalovirus (CMV) and Herpes Simplex Virus I and II, collectively known as ToRCH, are routinely checked in pregnant women in which the prevalence of these diseases is high. The diseases will transmit to the fetus during pregnancy or at birth, causing severe damages to newborn infants. Because of these complications, assessment of the immune status among pregnant women and women of child-bearing age is important. Probes corresponding to antigens specific for the five ToRCH markers, together with positive and negative controls are printed onto a multi-chamber chip as described previously. The biochip allows detection of IgG and IgM simultaneously in neighbouring chambers by adding either fluorescence labeled anti-human IgG antibodies or fluorescence labeled anti-human IgM antibodies to the respective chambers. The detection of IgM in ToRCH diagnosis is to allow early diagnosis of the diseases since IgM is an antibody that is produced soon after infection, while IgG is produced after a longer lag time. However IgG levels remain high for a much longer period of time even after the infection has been cured. Hence, a high level of IgM combined with a low level of IgG in a patient's sera is indicative of an on-going acute infection.

Methods:

1. Probes corresponding to the antigens isolated from Toxoplasma gondii 86, Rubella virus 88, Cytomegalovirus (CMV) 90 and Herpes Simplex Virus I 92 and II 94, human IgG positive control 96 and Human Serum Albumin (HSA) negative control 98 are printed repetitively onto test sites that are arranged in a 3x3 array or as shown

in Figure 5A. These different subgrids are defined within the same test area 100 that will be found in a single well when an appropriate divider is attached thereon. In the preferred embodiment, the biochip in this example contains eight test areas that are identical to the one shown in Figure 5A. Two tested areas are used for incubation with a positive serum while two others are used for the negative control serum. Two additional patient's sera can then be tested in this biochip in duplicates.

2. Immobilization, drying, blocking, reaction, washing are carried out as described in Example 2.
3. To detect ToRCH IgG in serum, fluorescence labeled anti-human IgG antibodies are used in one of the wells that has been incubated with the serum as indicated above.
4. To detect ToRCH IgM, fluorescence labeled anti-human IgM antibodies are added to the duplicate well that has been incubated previously with the respectively serum.
5. Figure 5B shows the experimental results of an assay using serum from a rubella virus infected patient. Positive signal was detectable in test molecule 88 and positive control 96.
6. Figure 5C shows the experimental results of an assay using serum of a CMV infected patient. Positive signal was detectable in test molecule 90 and positive control 96.

EXAMPLE 6

USE OF THE STREPTAVIDIN/BIOTIN SYSTEM AS A UNIVERSAL AMPLIFICATION SYSTEM

This embodiment uses the fluorescence/enzyme labeled streptavidin and biotin method (FLSAB/ELSAB) as an enhanced reporting system in protein chip analysis. In the current protein chip technology, fluorescence or enzyme conjugated antibodies are commonly used in the reporting system. This embodiment introduces a signal amplification step to the present reporting system. Sensitivity of protein chip increases by ten folds when using the amplification system. Therefore, less amount of probes may be used in printing. In return, background is reduced, signal to noise ratio increases and the chance of false positive results is minimized. It also facilitates the omission of a difficult step on labeling of fluorescence dye to acid protein.

Fabrication of protein chip:

1. Arraying of protein probes on solid substrates such as aldehyde slides, nitrocellulose or nylon membrane.
2. Protein probes on slides are dried to fix for overnight at room temperature or 1 hour at 37°C.
- 5 3. Substrate surface is blocked by blocking buffer containing bovine serum albumin (BSA) and tween 20 for 1 hour at 37°C.
4. Rinse with double distilled water and store dried at room temperature.

Methods:

- 10 1. Specimen sample is added into each chamber of protein chip and incubated at 37°C, 1hour.
2. Excessive specimen is washed with washing buffer and spun dry.
3. The chip is blocked with blocking buffer and washed with washing buffer as described before.
4. Wash and spin dry.
- 15 5. Biotin conjugated biomolecules which bind specifically to the target markers are diluted in blocking buffer, added into each chamber and incubated for 30min at 37°C.
6. Wash and spin dry.
7. Streptavidin is diluted in blocking buffer, added to the chip and incubated for 30min at 37°C.
- 20 8. Wash and spin dry.
9. Enzyme alkaline peroxidase (AP) or horse raddish peroxidase (HRP), or fluorescence conjugated biotin diluted in blocking buffer is added to the chip and incubated for 30min at 37°C in darkness.
- 25 10. If enzyme conjugated biotin is used in (9), appropriate chemiluminescent substrates, Luminol, Pierce Chemical Company (IL, USA) for HRP or 1,2-dioxetane-based substrate for ICN Biomedicals Inc. (CA, USA), are added and incubated at room temperature for 1 min. (according to the manufacturer's manual) After completion, the chip is washed, divider sheet is removed, and chip was spun dry and scanned with micoarray scanner.

30

EXAMPLE 7

METHOD AND DEVICE FOR CANCER DIAGNOSIS

This embodiment describes a high throughput and sensitive diagnostic method and biochip for cancers. This chip allows the detection of cancer at early stage and at the same time, determines the type and subtype of cancer. Probes are antibodies corresponding to tissue specific tumor marker; positive controls are the corresponding tumor markers.

5 Human serum albumin is the negative control.

Cancer chips are categorized according to the organ/tissue type. Each type of cancer chip consists of a panel of antibodies that react to tissue specific tumor markers. The expression profile in each antibody panel allows further subtyping of the cancer. For example, γ -GT I', II II' are found only in liver cancer; Concanavalin A reactive alpha-fetoprotein (R Con A AFP) are predominantly found in serum samples of primary liver cancer while in secondary liver cancer, gonadal and extra gonadal germ cell tumors had a significant reduction of R ConA AFP with elevation of nonreactive form. Therefore, the use of panels of tumor markers in cancer biochips will facilitate cancer diagnosis, typing and subtyping.

15 Figure 6A shows one test area in a cancer chip with 16 arrays (A1 to D4). Each array contains 9 discrete test sites with the same test molecule immobilized thereon. Array A1 has test molecule anti alpha-fetoprotein (AFP) antibody printed thereon; A2 is printed the anti gamma-glutamyl transferase (γ -GT) isozyme I antibody; A3 is printed the anti gamma-glutamyl transferase (γ -GT) isozyme I' antibody; A4 is printed the anti gamma-glutamyl transferase (γ -GT) isozyme II antibody; B1 is printed the anti gamma-glutamyl transferase (γ -GT) isozyme II' antibody; B2 is printed the anti des-gamma carboxy prothrombin (DPC) antibody; B3 is printed the anti alpha-L-fucosidase antibody; B4 prints the anti 5' nucleotide phosphodiesterases isozyme V antibody; C1 prints the anti glutathione S-transferase-placental form antibody; C2 prints the anti alpha-1-antitrypsin antibody; C3 prints the anti ferritin antibody; C4 prints the anti acidic isoform (AIF) antibody; D1 prints the anti hepatitis B surface antigen antibody; D2 and D3 print the positive controls corresponding to the 13 tumour markers and also human IgG; and D4 prints the negative control.

Figure 6B shows an example of the kinds of the diagnostic result that can be obtained from a liver-cancer patient, for example with positive signals detected in array A1, A3, A4, A5 and D1, and positive controls D2 and D3.

EXAMPLE 9

DIAGNOSIS OF AUTOIMMUNE DISORDER

Autoimmune diseases are characterized by the presence of high levels of circulating IgM and IgG autoantibodies in patient serum. There are two categories of autoimmune diseases: single organ or cell type, and systemic type. Example of the former type are autoimmune hemolytic anemia (AIHA) in which the body attacks its own red blood cells (RBC) with elevated level of IgG autoantibody and IgM antibody; Myasthenia gravis in which patient suffers from severe muscular weakness with elevated in autoantibodies to acetylcholine receptors; and Hashimoto thyroiditis in which anti-thyroglobulin antibody and antimicrobial antibody are elevated. Examples of the later are systemic lupus erythematosus (SLE) in which antinuclear ribonucleoprotein antibody (anti-dsDNA and anti-SM) are detected; and rheumatoid arthritis in which rheumatoid factor is detected.

Methods:

1. Autoimmune protein chip is to detect autoantibodies in sera of patients. Probes corresponding to antigens of autoimmune disease markers are printed on the multi-chamber chip for fabrication. The markers are antinuclear ribonucleoprotein antibody, rheumatoid factor, anti acetylcholine receptor antibody, anti red blood cell antibody, anti thyroglobulin antibody and antimicrobial antibody.

Example of the design of autoimmune diagnosis protein chip is illustrated in Figure 7A. Within the same test area (representing one well or chamber in the assembled device), 9 discrete arrays (A1 to C3) are defined. Each array is immobilized one type of molecule which is different from the other arrays. Within the same array, the 16 test sites (4x4) contain the identical test molecule. A1 prints the double stranded DNA molecule; A2 prints the SMITH antigen; A3 prints the acetylcholine receptor; B1 prints thyroglobulin; B2 prints microbial antigen; B3 prints abnormal IgG; C1 prints the human IgG positive control; C2 prints the negative control; and C3 prints red blood cell. SMITH is a complex of RNA and non-histone nuclear protein that helps DNA stay in its correct shape; it is released into the blood stream together with DNA upon cell lysis and is a marker for SLE.

2. Autoimmune protein chip is an indirect immuno-based assay. Patient sera are added into individual chamber. As in the previous example 8, each serum may be added to duplicate chambers for the detection of IgG as compared to the detection of IgM. Autoantibodies in the serum react with the stationary phase probes. After washing, a fluorescence labeled anti-human IgG antibody is added to the chamber for detection of cross-reaction IgG.

3. For the detection of cross-reaction bivalent or multivalent IgM, a double-antigen-sandwich method can also be applied in the autoimmune protein chip. After the reaction with serum, fluorescence label antigens are added to the reaction chamber for detection.
4. After reaction completion, biochips are scanned by a microarray scanner.

5 Figure 7B shows an example of the diagnostic result of a systemic lupus erythematosus patient. Positive signals will appear in test sites A1 and A2, and positive control site, C1.

 Figure 7C shows an example of the diagnostic result of rheumatoid arthritis patient. Positive signals will appear in test site B3 and positive control C1.

10 The detailed description for the specific embodiment above have been presented for the purposes of illustration and explanation. It is not intended to be exhaustive or to limit the invention to the precise forms disclosed, as many modifications and variations are possible in the light of the teaching provided. For example, it is clear that the arrangement shown in, Figures 4A to 4C is for illustration only and that smaller test areas may be defined
15 onto the same biochip. As an variation, three duplicates of test areas 56 and 58 may be provided on the same chip such that the test serum and the positive and negative sera may also be tested on same biochip. Furthermore, additional test area may also be defined on the biochip in combination with a suitable divider with the corresponding number of holes such that multiple patients' samples may be tested on the same biochps.

20 As a further example, the use of anti-human IgM and anti-human IgG antibodies for the diagnosis of acute infections by analysing the antibody profile of the patient may be applied to many diseases in addition to the one disclosed in example 5.

CLAIMS

1. A device for detecting multiple analytes comprising a solid substrate and a divider,
said substrate having a test surface with a plurality of discrete test sites defined
5 thereon, each said test site having a test molecule immobilized thereon;

said divider having a plurality of holes at predetermined positions provided on an
attachment surface, said attachment surface complementary to said test surface and
adapted for attachment thereto, said divider reversibly attachable onto said solid
substrate such that each said hole is adjoined with a portion of said test surface to
10 create a plurality of leak-proof chambers, said test surface within said chamber having
a plurality of test sites exposed therein, said chamber further having an opening that is
accessible from the exterior such that fluid introduced into said chamber may be
contacted with said exposed test sites for testing.
2. A device according to Claim 1 where in said test molecule is an antigen or an
15 antibody.
3. A device according to Claim 1 where in a cover is provided, said cover having a
covering surface adapted for closing said opening of said chamber to prevent spillage
or contamination between solutions in different chambers.
4. A device according to Claim 3 herein said cover is a polyester sheet.
- 20 5. A device for detection of multiple analytes comprising:

(a) a chip with a flat surface, said flat surface having a plurality of reaction areas
defined thereon, each said reaction area further containing at least one array of
discrete test sites, each said test site having a test molecule immobilized thereon,
and

25 (b) a divider sheet having a plurality of holes defined within a frame, each said hole
corresponding to a reaction area, said frame adapted for reversible coupling onto
said flat surface such that a plurality of leak-proof wells are created therebetween
with each reaction area forming the base of a corresponding well and the frame of
said sheet forming dividing walls between neighbouring wells.
- 30 6. A device according to Claim 5 where in said test molecule is an antigen or an
antibody.

7. A method of analysing multiple analytes in a sample comprising :

(a) defining a plurality of discrete and spatially separate test sites on at least one test area on a test surface;

5 (b) immobilizing a test molecule onto each of said test sites such that a plurality of test molecules are immobilized thereon;

(c) providing a fluid-proof barrier around each said test area;

(d) contacting each said test area with the appropriate test reagents and the sample for analysis;

(e) removing unreacted sample and reagent;

10 (f) removing said barrier; and

(g) analysing said test surface for reaction between the analyte in said sample and said test molecule.

8. A method of analysing multiple analytes from the same sample according to claim 7 wherein said test surface is one side of a chip, said test molecule is an antibody or a ligand, and said steps (d) and (e) further comprises the steps of :

15 incubating said sample with the immobilized test molecules in each test area for said analytes to bind thereto, said analyte being a cross-reacting ligand or antibody;

removing unbound material;

20 adding a mixture of appropriate secondary molecules to said reaction area and incubating therein, each said secondary molecule having a signal molecule coupled thereto, said secondary molecule further adapted to bind specifically with the appropriate analyte;

removing unbound secondary molecules; and

detecting the presence of said signal molecule on each of said test sites.

25 9. A method according to Claim 7 wherein said test molecule is a hormones, drug, receptor, enzyme, nucleic acid, antibiotic or ligand.

30 10. A method according to claim 7 wherein said secondary molecule is a secondary antibody that cross-reacts with said appropriate analyte; said signal molecule is a fluorescence molecule capable of emitting an emission photon upon excitation of an excitation photon, and said step of detecting the presence of said signal molecule

further comprises the steps of exciting said signal molecule with said excitation light, and using a detector to detect emission of the emission photon using a fluorescence detector.

11. A method according to claim 8 wherein said signal molecule is an enzyme, and said
5 step of detecting the presence of said signal molecule further comprises the steps of providing an appropriate substrate for said enzyme and incubating therewith, said enzyme adapted to convert said substrate into a coloured product that is deposited onto said test site.
12. A method according to Claim 8 wherein said secondary molecule is a secondary
10 antibody that cross reacts with said appropriate analytes, said signal molecule is biotin, and said step of detecting the present of said signal molecule further comprises contacting said signal molecule with strepavidin or avidin to allow binding thereto; removing unbound strepavidin or avidin; contacting said bound strepavidin or avidin with a solution containing secondary biotin, said secondary biotin conjugated with a
15 fluorescence molecule, said fluorescence molecule capable of emitting an emission photon; shining an excitation photon onto said chip and using a detector to detect the emission of an emission photon from said fluorescence molecule.
13. A method according to claim 6 wherein said test molecule is selected from a group comprising Hepatitis A viral Antigen, Hepatitis C viral Antigen, Hepatitis D viral
20 antigen, Hepatitis B surface antigen, Hepatitis B 'e' antigen, Hepatitis B Core antigen and Hepatitis E viral Antigen, antibody against Hepatitis B surface antigen, antibody against Hepatitis B 'e' antigen, antibody against alpha-fetoprotein antigen and antibody against Hepatitis D viral antigen.
14. A Method according to claim 6 wherein said test molecule is selected from a group
25 comprising Toxoplasma gondii, Rubella virus, Cytomegalovirus , Herpes Simplex Virus I and Herpes Simplex Virus II.
15. A method according to Claim 6 where in said test molecule is selected from a group comprising: anti-alpha-fetoprotein, anti-gramma-glutamyl transferase isozyme I
30 antibody, anti-gamma-glutamyl transferase isozyme I' antibody, anti-gamma-glutamyl transferase isozyme II antibody, anti-gamma-glutamyl transferase isozyme II' antibody, anti-des-gamma carboxy prothrombin antibody, anti-alpha-L-fucosidase antibody, anti-5' nucleotide phosphodiesterases isozyme V antibody, anti-glutathione S-transferase-placental form antibody, anti-apha-1-antitrypsin antibody, anti-ferritin

antibody, anti-acidic isoferritin antibody, and anti-hepatitis B surface antigen antibody.

16. A method according to Claim 6 where in said test molecule is selected from a group consisting of: single stranded nucleic acid, double stranded nucleic acid, the SMITH antigen; acetylcholine receptor, thyroglobulin, microsomal antigen, abnormal human IgG and red blood cell protein.

5




Fig. 1A




Fig. 1B




Fig. 1C




Fig. 1D




Fig. 1E

3/9




Fig. 2A




Fig. 2B




Fig. 2C




Fig. 2D

4/9




Fig. 3A







Fig. 3B

5/9



6/9





Fig. 4D





Fig. 4E





Fig. 5B




Fig. 5C




Fig 6A




Fig. 6B

9/9




Fig. 7A




Fig. 7B




Fig. 7C

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CN02/00209

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁷ : C12M1/20,G01N33/50,G01N33/53,C12Q1/70,C12Q1/68

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched(classification system followed by classification symbols)

IPC⁷ : C12M1/20,G01N33/50,G01N33/53,C12Q1/70,C12Q1/68

Documentation searched other than minimum documentation to the extent that such documents are included in the field searched

Electronic data base consulted during the international search(name of data base and, where practicable, search terms used)

WPI,CNPT,PAJ,EPODOC

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant claim No.
A	US 5874219 A, (AFFYMETRIX INC), C12Q1/68, 1999-02-23. See the abstract.	1-16
P,A	WO 01/34846 A2, (UNIV MINNESOTA), C12Q1/68, 2001-05-17. See the abstract.	1-16
P,A	CN2438121 Y, (WANG, Bin, and WANG, Mei), G01N33/53, 2001-07-04 See the abstract.	1-16
A	WO 99/04896 A1, (QIAGEN GENOMICS INC., RAPIGENE INC.), B01J19/00, 1999-02-04. See the abstract.	1-16

☐ Further documents are listed in the continuation of Box C.
 ☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not
considered to be of particular relevance"E" earlier document but published on or after the international filing
date"L" document which may throw doubts on priority claim(s) or
which is cited to establish the publication date of another
citation or other special reason(as specified)"O" document referring to an oral disclosure, use, exhibition or
other means"P" document published prior to the international filing date but later
than the priority date claimed"T" later document published after the international filing date or priority
date and not in conflict with the application but cited to understand
the principle or theory underlying the invention"X"document of particular relevance; the claimed invention cannot be
considered novel or cannot be considered to involve an inventive
step when the document is taken alone"Y"document of particular relevance; the claimed invention cannot be
considered to involve an inventive step when the document is
combined with one or more other such documents, such combination
being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

04 June 2002 (04.06. 02)

Date of mailing of the international search report

27 JUN 2002

Name and mailing address of the ISA/

The Chinese Patent Office
6, Xitucheng Road, Haidian District,
Beijing, 100088, China

Facsimile No. 86-010-62019451

Authorized officer

ZENG,Fanhui

Telephone No. 62093733



INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/CN02/00209

Patent document cited in search report	Publication date	Patent family members	Publication date
US5874219 A	1999-02-23	NONE	
WO01/34846 A2	2001-05-17	AU200136403 A	2001-06-06
CN2438121 Y	2001-07-04	NONE	
WO99/04896 A1	1999-02-04	AU8582598 A	1999-02-16
		EP0998347 A1	2000-05-10
		CN1265049 A	2000-08-30
		US6150103 A	2000-11-21
		HU200002488 A2	2000-11-28
		AU735546 B	2001-07-12
		JP2001510727T	2001-08-07
		NZ501968 A	2001-09-28

专利名称(译)	用于检测多种分析物的装置和方法		
公开(公告)号	EP1373467A1	公开(公告)日	2004-01-02
申请号	EP2002721953	申请日	2002-03-28
[标]发明人	CHEUNG TO LI BIN PENG YONGJI REN YIPING GE HAIPENG DENG FUQIAO DING LI LI HONGMEI CAI QIFENG CHEN YING		
发明人	CHEUNG, TO LI, BIN PENG, YONGJI REN, YIPING GE, HAIPENG DENG, FUQIAO DING, LI LI, HONGMEI CAI, QIFENG CHEN, YING		
IPC分类号	G01N33/53 C12M1/00 C12M1/20 C12M1/34 C12N15/09 C12Q1/68 C12Q1/70 G01N21/78 G01N33/50 G01N33/543 G01N33/566 G01N33/569 G01N33/574 G01N37/00		
CPC分类号	G01N33/54366 G01N33/54313		
代理机构(译)	KÖSTER , HAJO , DR.		
优先权	01126480.2 2001-08-14 CN 01132292.6 2001-11-23 CN 01126115.3 2001-07-12 CN 01112783.X 2001-04-27 CN 01113323.6 2001-07-11 CN 01105795.5 2001-03-28 CN 01126932.4 2001-09-29 CN 01126929.4 2001-09-29 CN		
其他公开文献	EP1373467A4		
外部链接	Espacenet		

摘要(译)

提供了一种用于检测至少一个样品中的多种分析物的装置。该装置包含具有测试表面的固体基质。在测试表面上定义至少一个反应区域，该反应区域包含至少一个离散测试位点阵列。这些测试位点中的每一个都具有固定在其上的测试分子，并且不同的测试位点可以具有固定在其上的不同测试分子。提供分隔器以附接到固体基板上。分隔器包括设置在附接表面上的多个孔。附接表面与固体装置的测试表面互补并且适于可逆地附接到其上，使得当附接两个部件时，每个孔与测试表面的一部分邻接以产生多个防漏。室。腔室内的测试表面包含在腔室内暴露的多个测试位置。每个腔室优选地设置有可从外部接近的开口，使得引入腔室的流体可以与暴露的测试部位接触以进行测试。在本发明的另一方面，提供了一种用于分析相同样品中的多种分析物的方法。

